EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access

Comparative Clinical Outcomes of Nusinersen and Gene Therapy in Spinal Muscular Atrophy Type 1

Juliette Ropars, Claude Cances, Rocio Garcia-Uzquiano, Marta Gomez-Garcia de la Banda, Christine Barnerias, Frédérique Audic, Julien Durigneux, Cécile Halbert, Lionelle Nkam, Vincent Laugel, Caroline Espil, Ulrike Walther-Louvier und 7 weitere

JAMA Network Open · 08.10.2025 · 8 (10) · e2536348

DOI: 10.1001/jamanetworkopen.2025.36348 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift JAMA Network Open, online erschienen am 08.10.2025. Verfasst von Juliette Ropars und 18 weiteren Autor:innen. Beteiligte Einrichtung: Reference Center for Neuromuscular Disorders, Pediatric Department, CHU Brest, Brest, France. Hauptthemen laut MEDLINE: Genetic Therapy, Oligonucleotides, Spinal Muscular Atrophies of Childhood. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Therapeutic advances have transformed the prognosis of spinal muscular atrophy (SMA). Given the lifelong implications of these innovative therapies, comparative data on their efficacy are urgently required.

Objective

To compare clinical outcomes of nusinersen and onasemnogene abeparvovec gene therapy as first-line treatments in children with SMA type 1 (SMA1). Design, Setting, and Participants This comparative effectiveness study used data from the French National SMA Registry from September 2016 to July 2024. The follow-up period started at treatment initiation and continued until July 22, 2024, or death. Children with genetically confirmed SMA1 (types a, b, or c) treated within 6 months of diagnosis with either nusinersen or gene therapy as first-line therapy and followed up for at least 24 months were included. Matching criteria included age, baseline score on the Children’s Hospital of Philadelphia Infant Test of Neuromuscular Disorders, and respiratory and nutritional status at treatment initiation. Exposure First-line treatment with either nusinersen or gene therapy. Main Outcomes and Measures Outcomes included respiratory and nutritional support needs, motor function, and unsatisfactory clinical response (UCR)— a composite of death, treatment switch (or, for gene therapy, addition) due to inadequate response, initiation of feeding support, and/or failure to achieve independent sitting.

Results

Among 1366 patients enrolled in the registry, 309 were diagnosed with SMA1. Twenty-four children in 12 matched pairs met inclusion criteria (14 [58%] male; mean [SD] age at treatment initiation, 6.1 [3.0] months [range, 2.3-11.9 months]). Three patients (1 receiving gene therapy [8%], 2 receiving nusinersen [17%]) died within the first year of treatment. At 2 years posttreatment, 1 of the 11 surviving patients treated with gene therapy (9%) required nutritional support vs 5 of 10 (50%) treated with nusinersen, and nocturnal ventilation was required in 5 of 11 (45%) receiving gene therapy vs 8 of 10 (80%) receiving nusinersen. Motor outcomes were comparable between groups (mean [SE] intrapair difference in CHOP-INTEND score evolution, −1.69 [1.24] points; P = .17). UCR occurred in 8 of 12 patients (67%) receiving nusinersen and 3 of 12 (25%) receiving gene therapy. Conclusions and Relevance In this comparative effectiveness study of children with SMA1, gene therapy was associated with lower incidence of UCR and fewer supportive care needs vs nusinersen. These exploratory findings warrant confirmation in larger studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Genetic TherapyOligonucleotidesSpinal Muscular Atrophies of ChildhoodHumansMaleFemaleInfantTreatment OutcomeChild, PreschoolRegistriesChildFrance

Substanzen

nusinersenOligonucleotides

Autor:innen und Institutionen

  • Reference Center for Neuromuscular Disorders, Pediatric Department, CHU Brest, Brest, France.
  • Laboratoire de Traitement de l'Information Médicale (LaTIM) INSERM UMR 1101, Brest, France.
  • Unité de Recherche Clinique Assistance Publique-Hôpitaux de Paris, Université Paris-Saclay, Direction de la Recherche Clinique Assistance Publique Hôpitaux de Paris, Paris, France.
  • Reference Center for Neuromuscular Disorders, Pediatric Clinical Research Unit/Pediatric Multi-Thematic Module CIC 1436, Neuropediatric Department, Toulouse University Hospital, Toulouse, France.
  • Reference Center for Neuromuscular Disorders, Neuropediatric Department, Hôpital Raymond Poincaré, Garches, France.
  • Reference Center for Neuromuscular Disorders, Neuropediatric Department, Hôpital Necker Enfants Malades, Paris, France.

Zitieren

APA

Ropars, J., Cances, C., Garcia-Uzquiano, R., Gomez-Garcia de la Banda, M., Barnerias, C., Audic, F., Durigneux, J., Halbert, C., Nkam, L., Laugel, V., Espil, C., Walther-Louvier, U., Davion, J. B., Isapof, A., Le Goff, L., Desguerre, I., Quijano-Roy, S., Grimaldi, L., & French SMA Registry Study Group (2025). Comparative Clinical Outcomes of Nusinersen and Gene Therapy in Spinal Muscular Atrophy Type 1. JAMA Network Open, 8(10), e2536348. https://doi.org/10.1001/jamanetworkopen.2025.36348

Vancouver

Ropars J, Cances C, Garcia-Uzquiano R, Gomez-Garcia de la Banda M, Barnerias C, Audic F, et al. Comparative Clinical Outcomes of Nusinersen and Gene Therapy in Spinal Muscular Atrophy Type 1. JAMA Network Open. 2025;8(10):e2536348. doi:10.1001/jamanetworkopen.2025.36348

BibTeX
@article{Ropars2025,
  author = {Ropars, Juliette and Cances, Claude and Garcia-Uzquiano, Rocio and Gomez-Garcia de la Banda, Marta and Barnerias, Christine and Audic, Frédérique and Durigneux, Julien and Halbert, Cécile and Nkam, Lionelle and Laugel, Vincent and Espil, Caroline and Walther-Louvier, Ulrike and Davion, Jean-Baptiste and Isapof, Arnaud and Le Goff, Laure and Desguerre, Isabelle and Quijano-Roy, Susana and Grimaldi, Lamiae and French SMA Registry Study Group, French SMA Registry Study Group},
  title = {Comparative Clinical Outcomes of Nusinersen and Gene Therapy in Spinal Muscular Atrophy Type 1},
  journal = {JAMA Network Open},
  year = {2025},
  volume = {8},
  number = {10},
  pages = {e2536348},
  doi = {10.1001/jamanetworkopen.2025.36348}
}
Kostenlos starten →